Search alternatives:
less decrease » mean decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
less decrease » mean decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
2921
Data Sheet 5_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.csv
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2922
Data Sheet 2_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.csv
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2923
Image 4_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.tif
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2924
Image 3_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.tif
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2925
Data Sheet 1_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.csv
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2926
Image 1_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.tif
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2927
Image 2_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.tif
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2928
Data Sheet 4_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.csv
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2929
Data Sheet 3_Liver X receptor agonist T0901317 alleviates sepsis-induced acute lung injury by enhancing macrophage autophagy.csv
Published 2025“…Analysis of the human transcriptome data revealed a significant negative correlation between LXRα and S100A8 (R = −0.98, p < 0.001).…”
-
2930
Study-related adverse events.
Published 2025“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
-
2931
Study flow chart.
Published 2025“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
-
2932
Study CONSORT diagram.
Published 2025“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”
-
2933
Data Sheet 1_The efficacy of ophiopogonanone B in treating the cough in mice infected with Mycoplasma pneumoniae.docx
Published 2025“…Subsequent immunohistochemistry and RT-PCR revealed a significant reduction (P < 0.01 or P < 0.05) in the proteins and mRNA expression levels of TRPA1, SP, and CGRP in the lung tissue of mice treated with high and medium doses of ophiopogonanone B.…”
-
2934
DataSheet1_Changes in serum uteroglobin level in type 2 diabetes mellitus patients.docx
Published 2024“…</p>Conclusions<p>Uteroglobin is a sensitive factor that was decreased even in prediabetes and increased upon treatment with drugs with anti-inflammatory effects. …”
-
2935
-
2936
-
2937
Data Sheet 1_Characterization of Ty21a immunostimulatory effects in the mouse bladder.pdf
Published 2025“…Indeed, CD8<sup>+</sup> T-cell infiltration following Ty21a<sup>FR</sup> was significantly decreased in TLR4- and MyD88-KO mice. …”
-
2938
This is the raw data used for this study.
Published 2025“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”
-
2939
Pre-operative versus post-operative symptoms.
Published 2025“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”
-
2940
Patient Demographics.
Published 2025“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”